"Национальный медицинский исследовательский центр онкологии (ФГБУ “НМИЦ онкологии” Минздрава России) - один из ведущих онкоцентров страны. Мы консультируем, обследуем и лечим жителей 15 территориальных образований Южного и Северо - Кавказского федеральных округов с общей численностью населения более 26 млн. человек, а также жителей других регионов России. Клиническая база НМИЦ онкологии составляет 744 койки. Лечение получают свыше 20 тысяч пациентов в год, 13 тысяч из них - высокотехнологичное хирургическое лечение. В онкоцентре оборудованы 25 операционных, где еженедельно проводится свыше 200 хирургических вмешательств. Основные виды деятельности окоцентра: лечебно-диагностическая, научная и образовательная деятельности."

During the past decade, Rostov Research Institute of Oncology conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 1 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rostov Research Institute of Oncology" #1 sponsor was "Federal Research Institute of Pediatric Hematology, Oncology and Immunology" with 2 trials, followed by "EirGenix, Inc." with 1 trials sponsored, "Eisai Limited" with 1 trials sponsored, "Gliknik Inc." with 1 trials sponsored and "Millennium Pharmaceuticals, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rostov Research Institute of Oncology" #1 collaborator was "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Rostov Research Institute of Oncology" are "Childhood Acute Lymphoblastic Leukemia" (2 trials), "Breast Cancer" (1 trials), "Gastric Cancer" (1 trials), "Mantle Cell Lymphoma" (1 trials) and "Metastatic Breast Cancer" (1 trials). Many other conditions were trialed in "Rostov Research Institute of Oncology" in a lesser frequency.

Most popular intervention types in "Rostov Research Institute of Oncology" are "Drug" (7 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Daunorubicin" (2 trials), "Alofanib" (1 trials), "Bortezomib" (1 trials), "Cranial irradiation" (1 trials) and "Cyclophosphamide 750 mg/m^2" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rostov Research Institute of Oncology" are 5 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Rostov Research Institute of Oncology". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Rostov Research Institute of Oncology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Rostov Research Institute of Oncology, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".